BR0214451A - conjugados do hormÈnio do crescimento humano quimicamente modificado - Google Patents

conjugados do hormÈnio do crescimento humano quimicamente modificado

Info

Publication number
BR0214451A
BR0214451A BRPI0214451-4A BR0214451A BR0214451A BR 0214451 A BR0214451 A BR 0214451A BR 0214451 A BR0214451 A BR 0214451A BR 0214451 A BR0214451 A BR 0214451A
Authority
BR
Brazil
Prior art keywords
human growth
chemically modified
modified human
growth hormone
hormone conjugates
Prior art date
Application number
BRPI0214451-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Rory F Finn
Wei Lao
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0214451A publication Critical patent/BR0214451A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BRPI0214451-4A 2001-11-20 2002-11-20 conjugados do hormÈnio do crescimento humano quimicamente modificado BR0214451A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Publications (1)

Publication Number Publication Date
BR0214451A true BR0214451A (pt) 2006-05-30

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0214451-4A BR0214451A (pt) 2001-11-20 2002-11-20 conjugados do hormÈnio do crescimento humano quimicamente modificado

Country Status (25)

Country Link
EP (1) EP1453859A2 (https=)
JP (2) JP2005525302A (https=)
KR (2) KR20070072924A (https=)
CN (1) CN1608079A (https=)
AP (1) AP2004003050A0 (https=)
AU (1) AU2002356990A1 (https=)
BR (1) BR0214451A (https=)
CA (1) CA2467731A1 (https=)
CO (1) CO5580794A2 (https=)
EA (2) EA200700431A1 (https=)
EC (1) ECSP045114A (https=)
GE (1) GEP20063860B (https=)
HR (1) HRP20040448A2 (https=)
HU (1) HUP0500997A2 (https=)
IL (1) IL162031A0 (https=)
IS (1) IS7268A (https=)
MA (1) MA27544A1 (https=)
MX (1) MXPA04004809A (https=)
NO (1) NO20042182L (https=)
OA (1) OA13063A (https=)
PL (1) PL374354A1 (https=)
RS (1) RS53104A (https=)
TN (1) TNSN04090A1 (https=)
WO (1) WO2003044056A2 (https=)
ZA (1) ZA200403907B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
PT3025726T (pt) * 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
KR20050093856A (ko) 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체 알카날
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
JP2008502301A (ja) * 2003-10-10 2008-01-31 ノボ ノルディスク アクティーゼルスカブ ペプチドの抱合
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
ES2642214T3 (es) * 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
KR20070042567A (ko) * 2004-08-31 2007-04-23 파마시아 앤드 업존 캄파니 엘엘씨 글리세롤 분지쇄 폴리에틸렌 글리콜 인간 성장 호르몬공액체, 이의 제조 방법 및 이의 사용 방법
BRPI0519430A2 (pt) * 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
EP2399893B1 (en) 2004-12-22 2018-08-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1836316A4 (en) * 2004-12-22 2009-07-22 Ambrx Inc PROCESS FOR EXPRESSION AND CLEANING OF RECOMBINANT HUMAN GROWTH HORMONE
EP1850878A2 (en) 2005-02-10 2007-11-07 Novo Nordisk A/S C-terminally pegylated growth hormones
CA2604222A1 (en) 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
CN101400646A (zh) * 2005-11-08 2009-04-01 Ambrx公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
WO2007070659A2 (en) 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0713963A2 (pt) * 2006-07-07 2012-11-27 Novo Nordisk Healthcare Ag conjugados de proteìna e métodos para sua preparação
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Il−21変異体
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
US9840546B2 (en) 2008-04-03 2017-12-12 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
MX344559B (es) 2008-04-29 2016-12-20 Ascendis Pharma As Compuestos de hormona de crecimiento humana recombinante unidos al peg.
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
AR072850A1 (es) * 2008-07-31 2010-09-22 Pharmaessentia Corp Conjugados peptido-polimero
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
JP5766118B2 (ja) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
MX337432B (es) 2009-12-15 2016-03-04 Ascendis Pharma As Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero.
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
KR20130115086A (ko) * 2010-05-17 2013-10-21 세빅스 인코포레이티드 페길화된 c-펩티드
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
JP6820841B2 (ja) 2014-11-06 2021-01-27 ファーマエッセンティア コーポレイション ペグ化インターフェロンのための投薬計画
SG11201703870UA (en) 2014-11-18 2017-06-29 Ascendis Pharma Endocrinology Div As Novel polymeric hgh prodrugs
PT3220892T (pt) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Formas de dosagem de hormona do crescimento de longa ação
AU2016228555B2 (en) * 2015-03-11 2021-12-23 Nektar Therapeutics Conjugates of an IL-7 moiety and a polymer
NZ740534A (en) 2015-09-18 2019-07-26 Univ Miyazaki Long-acting adrenomedullin derivative
AU2020233198B2 (en) 2019-03-04 2025-05-15 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
CN114539384B (zh) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DK0458064T3 (da) * 1990-05-04 1998-04-27 American Cyanamid Co Stabilisering af somatotropiner ved modificering af cysteinrester
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン,インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DK0851925T3 (da) * 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
ES2297889T3 (es) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL144361A0 (en) * 1999-01-29 2002-05-23 Hoffmann La Roche Gcsf conjugates
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
AU2002219021A1 (en) * 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
EA008505B1 (ru) 2007-06-29
AP2004003050A0 (en) 2004-06-30
EA200700431A1 (ru) 2008-02-28
CN1608079A (zh) 2005-04-20
EP1453859A2 (en) 2004-09-08
RS53104A (sr) 2006-10-27
JP2006321808A (ja) 2006-11-30
PL374354A1 (en) 2005-10-17
KR20050044858A (ko) 2005-05-13
TNSN04090A1 (fr) 2006-06-01
MXPA04004809A (es) 2004-08-11
NO20042182L (no) 2004-08-11
WO2003044056A2 (en) 2003-05-30
CO5580794A2 (es) 2005-11-30
OA13063A (en) 2006-11-10
JP2005525302A (ja) 2005-08-25
GEP20063860B (en) 2006-06-26
ECSP045114A (es) 2004-07-23
HRP20040448A2 (en) 2006-02-28
WO2003044056A3 (en) 2003-08-21
EA200400565A1 (ru) 2005-06-30
IL162031A0 (en) 2005-11-20
CA2467731A1 (en) 2003-05-30
MA27544A1 (fr) 2005-10-03
KR20070072924A (ko) 2007-07-06
HUP0500997A2 (en) 2007-11-28
ZA200403907B (en) 2007-12-27
AU2002356990A1 (en) 2003-06-10
IS7268A (is) 2004-05-17

Similar Documents

Publication Publication Date Title
BR0214451A (pt) conjugados do hormÈnio do crescimento humano quimicamente modificado
BR0316716A (pt) Conjugados quimicamente modificados do hormÈnio do crescimento humano
PT1079806E (pt) Preparacoes para a aplicacao de anti-inflamatorios, especialmente, agentes anti-septicos e/ou agentes de promocao da cura de feridas, no tracto respiratorio superior e/ou no ouvido
NO20064676L (no) Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre
DE69609982D1 (de) Lipopolyamine als transfectionsmittel und ihre pharmazeutischen anwendungen
BR9809304A (pt) "formulações de proteìna c ativada"
BR9610386A (pt) Utilização de um composto capaz de antagonizar, ao menos parcialmente, a atividade oncogênica da proteína mdm2, utilização de um scfv, dirigido contra o domínio 1-134 da proteína mdm2, utilização de um ácido nucléico codificado para um composto capaz de antagonizar a atividade oncogênica da proteína mdm2, vetor viral e composição farmacêutica
CY1106723T1 (el) Ν-τελικα μονοπεγυλιωμενα συζευγματα ανθρωπινης αυξητικης ορμονης, διεργασιες για την παρασκευη τους και μεθοδοι χρησης αυτων
WO1996023526A3 (en) Diagnostic imaging contrast agents with extended blood retention
BR0008403A (pt) Formulação farmacêutica para administração oral
NO20024586D0 (no) Metode og preparater for å forhindre hormoninduserte bivirkninger
BR0209177A (pt) Anticorpo especìfico a tumor recombinante e uso do mesmo
BR9911871B1 (pt) derivados de ácido fenoxiacético e composições farmacêuticas contendo os mesmos.
CY1108418T1 (el) Φαρμακευτικες συνθεσεις της ερυθροποιητινης
DE60140426D1 (de) Pharmazeutische zusammensetzung für muskelanabolismus
PT1112266E (pt) 4-amino-2-aril-pirimidinas substituidas, sua preparacao, sua utilizacao e composicoes farmaceuticas que as contem.
BR9711046A (pt) Ligando relacionado a fator de necrose de tumor.
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
CY1106633T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν χαλκο, σαλικυλικο οξυ και βιταμινη c
WO2004039326A3 (en) Propofol with cysteine
WO2002005830A3 (en) Extracts from crassulacean acid metabolism (cam) mechanism plants and uses thereof
BR0211192A (pt) Conjugados de progenipoietina quimicamente modificados
BR0212287A (pt) Proteìna de ligação caspase-8, sua preparação e uso
BR0211991A (pt) HormÈnio do crescimento humano modificado
BR0013840A (pt) Análogos monoméricos de insulina humana

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.

B15K Others concerning applications: alteration of classification

Ipc: C07K 14/61 (2006.01), A61K 47/60 (2017.01)